Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.

Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, Sinal CJ, Kulkarni PM, Thakur GA, Denovan-Wright EM.

Neuropharmacology. 2019 Jun;151:1-12. doi: 10.1016/j.neuropharm.2019.03.033. Epub 2019 Mar 30.


The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation.

Thapa D, Cairns EA, Szczesniak AM, Toguri JT, Caldwell MD, Kelly MEM.

Cannabis Cannabinoid Res. 2018 Feb 1;3(1):11-20. doi: 10.1089/can.2017.0041. eCollection 2018.


The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice.

Cairns EA, Szczesniak AM, Straiker AJ, Kulkarni PM, Pertwee RG, Thakur GA, Baldridge WH, Kelly MEM.

J Ocul Pharmacol Ther. 2017 Oct;33(8):582-590. doi: 10.1089/jop.2017.0037. Epub 2017 Jul 18.


Why support a separate medical access framework for cannabis?

Cairns EA, Kelly MEM.

CMAJ. 2017 Jul 17;189(28):E927-E928. doi: 10.1503/cmaj.170427. No abstract available.


The Endocannabinoid System as a Therapeutic Target in Glaucoma.

Cairns EA, Baldridge WH, Kelly ME.

Neural Plast. 2016;2016:9364091. doi: 10.1155/2016/9364091. Epub 2016 Jan 12. Review.


Seeing over the horizon - targeting the endocannabinoid system for the treatment of ocular disease.

Cairns EA, Toguri JT, Porter RF, Szczesniak AM, Kelly ME.

J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):253-65. doi: 10.1515/jbcpp-2015-0065. Review.


The fatty acid amide hydrolase inhibitor, URB597, promotes retinal ganglion cell neuroprotection in a rat model of optic nerve axotomy.

Slusar JE, Cairns EA, Szczesniak AM, Bradshaw HB, Di Polo A, Kelly ME.

Neuropharmacology. 2013 Sep;72:116-25. doi: 10.1016/j.neuropharm.2013.04.018. Epub 2013 May 3.


Supplemental Content

Loading ...
Support Center